Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells
Status:
Withdrawn
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot trial is to determine whether a conversion from calcineurin
inhibitors (CNI) and mycophenolate mofetil (MMF) to a regimen consisting of efalizumab and
sirolimus is associated with an increase in T regulatory cells, white cells that control the
immune system and can prevent autoimmune diseases like arthritis or rejection of foreign
organs,and does not result in an increase in acute rejection.